Dried blood-spot analysis can be used
in pharmaceutical as well as other settings to obtain detailed quantitative
data about the compounds in animals and human subjects, using small volumes of
blood. The stability of blood spots is often superior to frozen plasma or
serum samples.

Agilent already supports dried
blood-spot analysis for hole-punch methodologies, and this new product provides
an automated online system for direct LC/MS analysis.

"Developed with our partners at
Prolab Gmbh, this new system expands the capabilities of our existing line of
advanced LC/MS systems," said Lester Taylor, Agilent marketing director,
LC/MS Division. "High sensitivity quantitation of drugs is a key component
of pharmaceutical and clinical research, and the Agilent AACE LC/MS offers
customers a fully automated solution."

The AACE LC/MS uses the Agilent 6400 Series Triple Quadrupole LC/MS system to
perform quantitative analysis. Data processing is performed using Agilent
MassHunter software, providing a common user interface for research
laboratories that use other Agilent LC/MS systems.

Additional product features include:

A single software system that controls
analytical setup and sample analysis.

A camera to capture the card image and
record the barcode for easy sample tracking.

A shorter overall cycle time from one
injection to the next, achieved by overlapping the extraction step and
analytical cycle.

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is
the world's premier measurement company and a technology leader in chemical
analysis, life sciences, electronics and communications. The company's 18,700
employees serve customers in more than 100 countries. Agilent had net revenues
of $6.6 billion in fiscal 2011. Information about Agilent is available at www.agilent.com.